Suzanne Shu, professor of marketing at the Dyson School, examines the psychological factors of claiming early Social Security benefits.

Holly Prigerson, professor of sociology in medicine at Weill Cornell Medicine, discusses the stages of grief and prolonged grief disorder.

Eswar Prasad, professor of international trade policy and economics, answers questions about China's economy.

Kate Bronfenbrenner, senior lecturer at ILR, explains why the Biden administration does not engage in labor negotiations.

John Tobin-de la Puente, professor of practice at the Dyson school, says “One [biodiversity] project intends to conserve habitat, and they measure their own success by the hectares of forest restored or set aside and conserved. But the next project down the road, which also claims to be delivering biodiversity returns, what they’re interested in is preserving the hippo, or the rhino.”

Alexandra Lahav, professor of law, notes that more litigation against companies using forever chemicals should be anticipated.

Ken Rosenberg, retired conservation scientist at the Lab of Ornithology, discusses the possibility of flamingoes settling in new areas.

Erica Groshen, senior labor market advisor at ILR, discusses the school bus driver shortage.

Alex Colvin, dean of ILR, joins Bloomberg TV to talk about technology and the balance of power between labor and management.

Article discusses a new study by Vanessa Bohns, professor of organizational behavior, and a colleague at the London Business School, which shows that email receivers frequently presume that the sender expects a quick reply.

David Silbey, associate professor of history, says, “The Chinese like to use maps as assertions of their authority and power—or what they wish their authority or power was. The most recent famous examples are the nine-dash line maps that they've put out, claiming grand swaths of land in the South China Sea.”

Nick Fabrizio, professor of health policy, says, “This is a landmark day! Medicare has set the price for 10 drugs, sounding the alarm for drug companies. It could target 60 drugs by 2030... Call it negotiation or price control, but the government has just furthered on its promise to lower health care costs for all Americans.”